Insomnia Disorder Clinical Trial
Official title:
Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder
Verified date | April 2020 |
Source | Idorsia Pharmaceuticals Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Status | Completed |
Enrollment | 360 |
Est. completion date | June 20, 2017 |
Est. primary completion date | April 12, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility |
Principal inclusion Criteria: - Signed informed consent prior to any study-mandated procedure. - Male or female aged 18-64 years (inclusive). - Women of childbearing potential must have negative pregnancy tests and use reliable methods of contraception up to 30 days after EOT. - Body mass index (BMI): 18.5 = BMI (kg/m2) < 32.0. - Insomnia disorder according to DSM-5 criteria. - Insufficient sleep quantity as collected subjectively in the sleep diary and validated objectively by polysomnography. - Insomnia Severity Index score = 15. Principal exclusion Criteria: - Any current history of sleep disorder other than insomnia, or any lifetime history of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy. - Self-reported usual daytime napping = 1 hour per day, and = 3 days per week. - Caffeine consumption = 600 mg per day. - Shift work within 2 weeks prior to the screening visit, or planned shift work during study. - Travel = 3 time zones within 1 week prior to the screening visit, or planned travel > or= 3 time zones during study. - Hematology or biochemistry test results deviating from the normal range to a clinically relevant extent as per judgment of the Investigator. - AST and/or ALT > 2 × ULN and/or direct bilirubin > 1.5 × ULN (except known history of Gilbert's syndrome). - Severe renal impairment (known or defined as estimated creatinine clearance < 30 mL/min). - History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments. - Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol. |
Country | Name | City | State |
---|---|---|---|
Germany | Investigator Site | Berlin | |
Germany | Investigator Site | Berlin | |
Germany | Investigator Site | Berlin | |
Germany | Investigator Site | Dresden | |
Germany | Investigator Site | Hamburg | |
Germany | Investigator Site | Hamburg | |
Germany | Investigator Site | Hannover | |
Germany | Investigator Site | Schwerin | |
Germany | Investigator Site | Schwerin | |
Hungary | Investigator Site | Budapest | |
Hungary | Investigator Site | Szeged | |
Hungary | Investigator Site | Törökbálint | |
Israel | Investigator Site | Beer Sheva | |
Israel | Investigator Site | Haifa | |
Spain | Investigator Site | Barcelona | |
Spain | Investigator Site | Barcelona | |
Spain | Investigator Site | Madrid | |
Spain | Investigator Site | Zaragoza | |
Sweden | Investigator Site | Göteborg | |
Sweden | Investigator Site | Örebro | |
United States | Investigator Site | Atlanta | Georgia |
United States | Investigator Site | Brandon | Florida |
United States | Investigator Site | Chicago | Illinois |
United States | Investigator Site | Cincinnati | Ohio |
United States | Investigator Site | Clearwater | Florida |
United States | Investigator Site | Coral Gables | Florida |
United States | Investigator Site | DeLand | Florida |
United States | Investigator Site | Hollywood | Florida |
United States | Investigator Site | Indianapolis | Indiana |
United States | Investigator Site | Las Vegas | Nevada |
United States | Investigator Site | Miami | Florida |
United States | Investigator Site | New York | New York |
United States | Investigator Site | Novi | Michigan |
United States | Investigator Site | Santa Monica | California |
United States | Investigator Site | Upland | California |
Lead Sponsor | Collaborator |
---|---|
Idorsia Pharmaceuticals Ltd. |
United States, Germany, Hungary, Israel, Spain, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 | WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG) | Baseline and Days 1&2 | |
Secondary | Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2 | LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG | Baseline and Days 1&2 | |
Secondary | Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4 | sLSO is the self-reported time to fall asleep, as reported in the sleep diary | Baseline and Week 4 | |
Secondary | Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4 | sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary. | Baseline and Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00821041 -
Internet-based Treatment for Chronic Insomnia
|
Phase 2 | |
Completed |
NCT03727438 -
Provider Supported Self-Help Cognitive Behavioral Therapy for Insomnia (Tele-Self CBTI)
|
N/A | |
Recruiting |
NCT03633305 -
Optimization of Insomnia Treatment in Primary Care
|
N/A | |
Completed |
NCT04616157 -
Internet-based Cognitive Behavioral Therapy for Adolescents With Sleep Problems- a Feasibility Trial
|
N/A | |
Completed |
NCT03679884 -
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
|
Phase 3 | |
Recruiting |
NCT04752254 -
Investigating Racing Thoughts in Patients With Insomnia Disorder
|
||
Completed |
NCT05558865 -
Effectiveness of a Digital Health Application for People With Insomnia Disorder (Somnovia)
|
N/A | |
Completed |
NCT05541055 -
Digital CBT-I for Insomnia Disorder
|
N/A | |
Active, not recruiting |
NCT06393504 -
Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
|
||
Completed |
NCT02841709 -
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
|
Phase 2 | |
Completed |
NCT03328585 -
Telemedicine vs. In-person Delivery of Cognitive Behavioral Treatment of Insomnia: a Mixed Methods Analysis
|
N/A | |
Completed |
NCT02952820 -
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
|
Phase 3 | |
Recruiting |
NCT05408078 -
Become Your Own SLEEPexpert: a Behavioral Treatment Program for Insomnia in Patients With Psychiatric Disorders
|
N/A | |
Recruiting |
NCT05780983 -
Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
|
N/A | |
Completed |
NCT03575104 -
Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
|
Phase 3 | |
Not yet recruiting |
NCT06279286 -
Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
|
Phase 1/Phase 2 | |
Terminated |
NCT02571595 -
A Sleep Program to Improve Sleep Quality in People With HIV
|
N/A | |
Completed |
NCT00984698 -
A Trial of Group Psychotherapy for Veterans and Military Personnel With Post Traumatic Stress Disorder (PTSD)
|
N/A | |
Recruiting |
NCT05780177 -
Brief Behavioral Treatment for Insomnia in Veterans With Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT05805527 -
Evaluating the Validity and Acceptability of a Fully-automated Interview to Diagnose Insomnia Disorder: a Pilot Study
|